---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-116945"
form_type: "8-K"
ticker: "MXCT"
cik: "0001287098"
company_name: "MAXCYTE, INC."
filed_at: "2021-09-17T23:59:59+00:00"
generated_at: "2026-06-29T02:53:56.606180+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# MaxCyte Q2 revenue up 38% to $7.1M, net loss widens to $4.4M; guides FY2021 revenue ~$30M

## Summary
- Revenue $7.1M (+38% YoY); cell therapy ex-SPL $4.8M (+59%), drug discovery $1.8M (+60%).
- Net loss $4.4M vs $3.0M; operating expenses $10.7M (+43%) on higher comp and professional costs.
- Signed two new SPL agreements with Celularity and Sana Biotechnology for cell therapy platform.
- Completed US IPO on Nasdaq raising $201.8M gross proceeds; cash $73.4M at June 30 pre-IPO.
- Preliminary FY2021 revenue guidance of approximately $30M.

## SEC filing metadata
- accession: 0001104659-21-116945
- form_type: 8-K
- ticker: MXCT
- cik: 0001287098
- company_name: MAXCYTE, INC.
- filed_at: 2021-09-17T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1287098/000110465921116945/0001104659-21-116945-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1287098/000110465921116945/tm2127942d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-116945
- JSON: https://secwatch.observer/filing/0001104659-21-116945.json
- Plain text: https://secwatch.observer/filing/0001104659-21-116945.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.